Biogen Idec Reports First Quarter 2004 Earnings per Share of $0.40 (Adjusted Non-GAAP); - - - On a GAAP Basis, First Quarter Loss per Share of $0.12 Primarily Due to Merger-Related Accounting Impacts - - - First Quarter Revenues Up 24% (vs. Prior Year Pro Forma) - - - U.S. filing for ANTEGREN(R) (natalizumab) as a Treatment for Multiple Sclerosis (MS) On Track for Submission in the Second Quarter - - -.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    PR Newswire. 2004.